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For a new formulation of an existing drug, as well as for generics, one
has only to demonstrate pharmacokinetic (PK) bioequivalence with
the original formulation to obtain registration. This PK tests are
performed in healthy young volunteers, taking for granted that PK
follows pharmacodynamics (PD). However, this methodology hardly
takes in account potential gender, size, age, maturation specific
differences in bioequivalence. FDA and EMA-regulation on pediatric
drug research have tried to find a compromise between minimal
exposure of children to a pediatric research program, and acquiring
minimal PK/PD and safety-data in children to reassure safe
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prescription of the drug, and therefore do not request bioequivalence
studies in the pediatric age.
The aim of this overview was to question if bioequivalence between
different solutions is similar over all populations.
Desmopressin (dDAVP), a synthetic vasopressin analogue,
is a level 1, grade A treatment of monosymptomatic enuresis nocturna
(MNE). This oligopeptide was studied because of the low
biodisponibility with large variation, and existing PK/PD data from
previous studies1.
Integrating the data of the different studies on different formulations, 
we observe
• A higher PD effect for dDAVP lyophilisate (MELT) to tablet, when 
adjusted with nutrition (Fig.1 a-b-c (Ref.1))
• A higher PK bioequivalent dose for lyophilisate (MELT) in children 
than in adults (Fig.2 (Ref.2))
• Compared with previous literature:
Fig. 1a: Superiority of  PD desmopressin melt 120 µg vs tablet 200µg
Fig.1b: Superiority of  PD desmopressin melt 120 µg versus 200µgtablet
1. The relative bioavailability between the lyophilisate and tablet 
formulations is probably not the same in children as in adults 
2. Poor correlation between circulating PK and PD-effect (hysteresis-
effect)
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Conclusion: This overview demonstrates that for an
oligopeptide like dDAVP, with a narrow safety-profile,
PK/PD bioequivalence of doses within the therapeutic
range in children, cannot be extrapolated from adult data.
This suggests that minor changes in formulation makes
appropriate bioequivalence studies in children mandatory
and collection of safety-data required.
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Fig.1c: Superiority of  PD desmopressin melt 120 µg versus 200µgtablet
Fig.2: Simulated dDAVP plasma concentrations for four different scenarios (200µg tablet/150 µg 
lyophilisate (MELT) – fed/fast (food effect)) suggest that 150 µg instead of 120 µg is equivalent to 
200µg tablet.
